Sutro Biopharma, Inc. STRO
$20.48
-3.89%
at last close
Analyst Consensus
- Consensus Rating
- Buy (9 Buy · 0 Hold · 0 Sell)
- Average Price Target
- $47.22
- Implied Upside
- +130.6%
- Price Target Range
- $27.00 – $60.00
- Analysts (12 mo)
- 9
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-08-13 | CitizensReni J. Benjamin |
Maintains | Market outperform | $41 → $34 |
| 2026-08-13 | WedbushDavid Nierengarten |
Reiterates | Outperform | $60 |
| 2026-06-11 | Truist SecuritiesSupawat Thongthip |
Assumes | Buy | $50 |
| 2026-05-28 | BarclaysLukas Shumway |
Initiates coverage on | Overweight | $56 |
| 2026-05-15 | Leerink Partners |
Maintains | Outperform | $38 → $43 |
| 2026-05-15 | WedbushDavid Nierengarten |
Upgrades | Neutral → Outperform | $22 → $60 |
| 2026-05-15 | HC Wainwright & Co.Andres Y. Maldonado |
Maintains | Buy | $28 → $50 |
| 2026-04-30 | MizuhoSalim Syed |
Initiates coverage on | Outperform | $50 |
| 2026-04-23 | CitizensReni J. Benjamin |
Maintains | Market outperform | $35 → $41 |
| 2026-04-17 | CitizensReni J. Benjamin |
Maintains | Market outperform | $23 → $35 |
| 2026-04-07 | Leerink Partners |
Initiates coverage on | Outperform | $38 |
| 2026-03-25 | Deutsche BankJames Shin |
Maintains | Buy | $51 → $55 |
| 2026-03-24 | Wells FargoEva Fortea Verdejo |
Upgrades | Equal-weight → Overweight | $8 → $27 |
| 2026-03-24 | HC Wainwright & Co.Andres Y. Maldonado |
Upgrades | Neutral → Buy | $10 → $28 |
| 2026-01-20 | CitizensReni Benjamin |
Upgrades | Market perform → Market outperform | $23 |
| 2025-12-22 | HC Wainwright & Co.Andres Y. Maldonado |
Maintains | Neutral | $2 → $10 |
| 2025-08-12 | Wells FargoDerek Archila |
Maintains | Equal-weight | $4 → $3 |
| 2025-06-16 | Piper SandlerEdward Tenthoff |
Upgrades | Neutral → Overweight | $2 |
| 2025-05-19 | B of A SecuritiesTazeen Ahmad |
Maintains | Underperform | $1 → $1 |
| 2025-04-29 | HC Wainwright & Co.Andres Maldonado |
Reiterates | Neutral | $2 |
| 2025-03-17 | HC Wainwright & Co.Andrew Fein |
Downgrades | Buy → Neutral | $12 → $2 |
| 2025-03-14 | Citizens Capital MarketsReni Benjamin |
Downgrades | Market outperform → Market perform | — |
| 2025-03-14 | WedbushDavid Nierengarten |
Downgrades | Outperform → Neutral | $8 → $2 |
| 2025-03-14 | B of A SecuritiesTazeen Ahmad |
Downgrades | Buy → Underperform | $11 → $1 |
| 2024-12-11 | Wells Fargo |
Maintains | Equal-weight | $5 → $4 |
| 2024-12-11 | JMP SecuritiesReni Benjamin |
Reiterates | Market outperform | $17 |
| 2024-11-18 | HC Wainwright & Co.Andrew Fein |
Reiterates | Buy | $12 |
| 2024-10-11 | Piper SandlerEdward Tenthoff |
Reiterates | Overweight | $11 |
| 2024-10-11 | HC Wainwright & Co.Andrew Fein |
Reiterates | Buy | $12 |
| 2024-09-16 | JMP SecuritiesReni Benjamin |
Reiterates | Market outperform | $17 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $20.48
- Market Cap
- $339.58 million
- 52-Week Range
- $7.15 – $43.85
- Average Volume
- 319K shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.